BCTX Research and Charts

BCTX - BriaCell Therapeutics Corp (Healthcare: Biotechnology)

Projected Earnings Date: 2024-09-14 (Delayed quote data 2025-06-30)

Last 2.94	Change ⇓ -0.02 (-0.68%)	Volume 70,024
	Open 2.96	High 3.05	Low 2.92

8EMA (Daily) 3.02	40EMA (Daily) 3.33	50EMA (Daily) 3.37	STO (Daily) 24.634	MACD Hist (Daily) -0.026
8EMA (Weekly) 3.192	40EMA (Weekly) 2.88	50EMA (Weekly) 2.83	STO (Weekly) 4.361	MACD Hist (Weekly) -0.327


Company Profile
BriaCell Therapeutics Corp is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell, in collaboration with Incyte Corp., is conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a Combination Study with Incyte drugs, INCMGA00012, and epacadostat, in advanced breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing and is designed to produce a potent and selective immune response against the cancer of each patient eliminating the time, expense and complex manufacturing logistics associated with immunotherapies.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.